AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37971194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily followed by venetoclax ramp-up to 400 mg daily for 22 additional 4-week cycles
Number of subjects: 45
Study 37971194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib and venetoclax
Number of subjects: 45
Study 37971361 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral monocyte subset gating strategy using flow cytometry (FCM)
Number of subjects: 20
Study 37971487 — intervention group
Group type: EXPERIMENTAL
Intervention: Aktiia Bracelet (cuffless optical BP device)
Number of subjects: 35
Study 37971487 — intervention group
Group type: COMPARATOR
Intervention: Austiatory measurements (reference method)
Number of subjects: 35
Study 37971503 — intervention group
Group type: EXPERIMENTAL
Intervention: Early time-restricted carbohydrate consumption (eTRC)
Number of subjects: 28
Study 37971503 — intervention group
Group type: COMPARATOR
Intervention: Conventional dieting (control)
Number of subjects: 28
Study 37971648 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric Advanced Warning Score (PAWS) measured every 8 hours
Number of subjects: 2868
Study 37971677 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment by Triage Clinicians (TC) and Study Team (ST) of medical students using a smartphone application.
Number of subjects: 1349
Study 37971677 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment by Triage Clinicians (TC) and geriED trained nurses (geriED-TN).
Number of subjects: 1349
Study 37971677 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) assessment by Study Team (ST) of medical students and geriED trained nurses (geriED-TN).
Number of subjects: 1349
Study 37971677 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS assessment at triage.
Number of subjects: 1349
Study 37971692 — intervention group
Group type: EXPERIMENTAL
Intervention: ORZ-fortified canola oil
Number of subjects: 92
Study 37971692 — intervention group
Group type: COMPARATOR
Intervention: Plain canola oil
Number of subjects: 92
Study 37971692 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 92
Study 37971692 — intervention group
Group type: EXPERIMENTAL
Intervention: All three groups
Number of subjects: 92
Study 37971723 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab, 6 mg, intravitreal injection every 4 weeks
Number of subjects: 517
Study 37971723 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept, 2 mg, intravitreal injection every 4 weeks
Number of subjects: 517
Study 37971722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg intravenously) administered every 28 days for 4 doses
Number of subjects: 33
Study 37971786 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37971800 — intervention group
Group type: EXPERIMENTAL
Intervention: SparkRx (self-guided, mobile app-based behavioral activation therapy)
Number of subjects: 223
Study 37971800 — intervention group
Group type: COMPARATOR
Intervention: Assessment-enhanced usual care (control)
Number of subjects: 223
Study 37971800 — intervention group
Group type: EXPERIMENTAL
Intervention: SparkRx
Number of subjects: 223
Study 37971811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 149
Study 37971811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure + Sertraline (PE + sertraline)
Number of subjects: 149
Study 37971859 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 sessions of neurofeedback (NF)
Number of subjects: 133
Study 37971871 — intervention group
Group type: EXPERIMENTAL
Intervention: TV005
Number of subjects: 65
Study 37971871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 37972038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 204
Study 37972038 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with panretinal photocoagulation
Number of subjects: 204
Study 37972091 — intervention group
Group type: EXPERIMENTAL
Intervention: High bed occupancy (90% of nationwide beds occupied)
Number of subjects: 252
Study 37972091 — intervention group
Group type: COMPARATOR
Intervention: Low bed occupancy (below 90% of nationwide beds occupied)
Number of subjects: 252
Study 37972346 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable HPV ctDNA on dPCR at the end of CRT, 4-6 weeks post-CRT, and 3 months post-CRT
Number of subjects: 70
Study 37972346 — intervention group
Group type: COMPARATOR
Intervention: Undetectable HPV ctDNA
Number of subjects: 70
Study 37972628 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ultrasound therapy
Number of subjects: 40
Study 37972659 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR inhibitors (FGFRi) therapy
Number of subjects: 17
Study 37972659 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR2-BICC1 fusion introduction in biliary tract cells
Number of subjects: 17
Study 37972659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEK inhibition with FGFRi
Number of subjects: 17
Study 37972659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FGFRi and MEK inhibition in an in vivo animal model
Number of subjects: 17
Study 37972723 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 0
Study 37972723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigatuzumab
Number of subjects: 0
Study 37972895 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food omnivorous meal (MEAT) containing 100 g lean ground beef, 0.45 g protein/kg body mass
Number of subjects: 16
Study 37972895 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous whole-food vegan meal (PLANT)
Number of subjects: 16
Study 37972929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle block (30 ml of ropivacaine 0.5%)
Number of subjects: 60
Study 37972929 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block at the popliteal crease (30 ml of ropivacaine 0.5% + saphenous nerve block)
Number of subjects: 60
Study 37973184 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging of Myocardial α
Number of subjects: 0
Study 37973206 — intervention group
Group type: EXPERIMENTAL
Intervention: 24/7 home palliative care (PC) service
Number of subjects: 2831
Study 37973206 — intervention group
Group type: COMPARATOR
Intervention: Oncological population exposed to 24/7 PC
Number of subjects: 2831
Study 37973340 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for recent alcohol abstinence (group 2 and group 4)
Number of subjects: 680
Study 37973340 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for isoniazid adherence (group 3 and group 4)
Number of subjects: 680
Study 37973340 — intervention group
Group type: COMPARATOR
Intervention: No incentives (group 1)
Number of subjects: 680
Study 37973340 — intervention group
Group type: COMPARATOR
Intervention: No incentives for isoniazid adherence (group 1 and group 2)
Number of subjects: 680
Study 37973342 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for religious leaders incorporating cultural, theological, and medical teaching about family planning.
Number of subjects: 24
Study 37973342 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no intervention).
Number of subjects: 24
Study 37973342 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for religious leaders.
Number of subjects: 24
Study 37973342 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities during the COVID-19 pandemic.
Number of subjects: 24
Study 37973472 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA1) - Local EA with two abdominal acupoints, administered daily for 4 days.
Number of subjects: 89
Study 37973472 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA2) - Local plus distal EA with twelve peripheral acupoints, administered daily for 4 days.
Number of subjects: 89
Study 37973472 — intervention group
Group type: COMPARATOR
Intervention: Control - Conventional standard-of-care therapy for AP, no EA treatment.
Number of subjects: 89
Study 37973472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EA (EA1 + EA2)
Number of subjects: 89
Study 37973477 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (tE2) patches
Number of subjects: 251
Study 37973477 — intervention group
Group type: COMPARATOR
Intervention: Luteinising hormone releasing hormone analogues (LHRHa)
Number of subjects: 251
Study 37973545 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut, sesame and tree nut allergy assessment through skin testing, specific IgE measurements and oral food challenges.
Number of subjects: 240
Study 37973545 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of the development of peanut, sesame and tree nut allergies in the first 3 years of life.
Number of subjects: 240
Study 37973548 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Sentry handpiece (AS)
Number of subjects: 1432
Study 37973548 — intervention group
Group type: COMPARATOR
Intervention: Non-AS handpiece
Number of subjects: 1432
Study 37973659 — intervention group
Group type: COMPARATOR
Intervention: Raising Healthy Children (RHC) intervention
Number of subjects: 298
Study 37973713 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 subtype A in Ukrainian patients
Number of subjects: 117
Study 37973713 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 subtype B in Polish patients
Number of subjects: 117
Study 37973713 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of drug resistance mutations
Number of subjects: 117
Study 37973713 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug resistance mutations in Polish patients
Number of subjects: 117
Study 37973713 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of transmission of multidrug resistant HIV strains
Number of subjects: 117
Study 37973784 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs) or antiviral drugs for COVID-19
Number of subjects: 0
Study 37973784 — intervention group
Group type: COMPARATOR
Intervention: Other drug treatment strategies (control group)
Number of subjects: 0
Study 37973795 — intervention group
Group type: EXPERIMENTAL
Intervention: Carborie (400 ml)
Number of subjects: 80
Study 37973795 — intervention group
Group type: COMPARATOR
Intervention: Plain water (400 ml)
Number of subjects: 80
Study 37973806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging-guided lymphadenectomy
Number of subjects: 258
Study 37973806 — intervention group
Group type: COMPARATOR
Intervention: Non-ICG group (conventional laparoscopic lymphadenectomy)
Number of subjects: 258
Study 37973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 210
Study 37973856 — intervention group
Group type: COMPARATOR
Intervention: Balloon pre-dilatation stenting
Number of subjects: 210
Study 37973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 210
Study 37973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary glycoprotein IIb/IIIa inhibitors
Number of subjects: 210
Study 37973887 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 149
Study 37973887 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models (logistic regression)
Number of subjects: 149
Study 37973887 — intervention group
Group type: COMPARATOR
Intervention: Validation cohort (86 patients with cirrhosis)
Number of subjects: 149
Study 37973901 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus TQB2450 (benmelstobart)
Number of subjects: 31
Study 37973956 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA mutations detected
Number of subjects: 54
Study 37973956 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA mutations
Number of subjects: 54
Study 37973956 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression in small EVs
Number of subjects: 54
Study 37974056 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 4659 at high dose (1 × 10^11 CFU/day)
Number of subjects: 0
Study 37974056 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 4659 at low dose (1 × 10^9 CFU/day)
Number of subjects: 0
Study 37974056 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 4659
Number of subjects: 0
Study 37974078 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded recession of inferior oblique muscle (8 mm for amplitude 15 PD to 20 PD with mild IOOA, 10 mm for amplitude 20-30 PD with moderate IOOA, maximum recession for amplitude >30 PD with marked IOOA)
Number of subjects: 40
Study 37974078 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded recession of inferior oblique muscle
Number of subjects: 40
Study 37974084 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus of norepinephrine
Number of subjects: 35
Study 37974084 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of norepinephrine
Number of subjects: 35
Study 37974112 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention group (e-learning platform, networking platform, and digital care documentation)
Number of subjects: 110
Study 37974112 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention group (e-learning and networking platforms)
Number of subjects: 110
Study 37974112 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual home care)
Number of subjects: 110
Study 37974126 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Contact letters sent by CareSource
Number of subjects: 43000
Study 37974126 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 43000
Study 37974158 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered substance use screening and brief intervention program
Number of subjects: 100
Study 37974160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions (up to eight infusions, twice-weekly over four weeks)
Number of subjects: 0
Study 37974160 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active comparator, twice-weekly over four weeks)
Number of subjects: 0
Study 37974160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions
Number of subjects: 0
Study 37974184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous idursulfase
Number of subjects: 55
Study 37974189 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Planning group (AP; 'traditional' BA)
Number of subjects: 60
Study 37974189 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Engagement group (AE; 'experiential' BA)
Number of subjects: 60
Study 37974189 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (WL)
Number of subjects: 60
Study 37974223 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation (HFS)
Number of subjects: 69
Study 37974223 — intervention group
Group type: COMPARATOR
Intervention: Interactive video-case challenge (IVC)
Number of subjects: 69
Study 37974229 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable hip orthosis during overground gait training
Number of subjects: 8
Study 37974234 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-game based swallowing function training
Number of subjects: 78
Study 37974234 — intervention group
Group type: COMPARATOR
Intervention: Conventional swallowing function training
Number of subjects: 78
Study 37974245 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person visits
Number of subjects: 200
Study 37974245 — intervention group
Group type: COMPARATOR
Intervention: Telehealth
Number of subjects: 200
Study 37974265 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPS Electronic Spanish Platform (TAPS-ESP)
Number of subjects: 1000
Study 37974284 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based BCI-assisted MI training
Number of subjects: 0
Study 37974284 — intervention group
Group type: COMPARATOR
Intervention: MI training alone (no BCI)
Number of subjects: 0
Study 37974280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring plus treatment guideline
Number of subjects: 1601
Study 37974280 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1601
Study 37974333 — intervention group
Group type: EXPERIMENTAL
Intervention: eW system (adjustable glaucoma drainage device combined with a novel orbital filtering plate)
Number of subjects: 42
Study 37974502 — intervention group
Group type: EXPERIMENTAL
Intervention: Roy adaptation model-based strengthening program (RAMBSP) for 12 weeks online group sessions
Number of subjects: 105
Study 37974502 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 105
Study 37975059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous branched chain amino acids (IV-BCAA) - 500 mL/day for 3 days + Lactulose; n = 39
Number of subjects: 70
Study 37975059 — intervention group
Group type: COMPARATOR
Intervention: Lactulose alone; n = 37
Number of subjects: 70
Study 37975371 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Tislelizumab plus chemotherapy (XELOX regimen: Xeloda plus Oxaliplatin)
Number of subjects: 0
Study 37975371 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone (XELOX regimen)
Number of subjects: 0
Study 37975434 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA101 (40-60 IU/kg)
Number of subjects: 30
Study 37975434 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA101 (12.5 IU/kg)
Number of subjects: 30
Study 37975434 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA101
Number of subjects: 30
Study 37975501 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus (PIB) erector spinae plane block (ESPB)
Number of subjects: 80
Study 37975501 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve block with patient-controlled intravenous analgesia (ICNB-PCIA)
Number of subjects: 80
Study 37975597 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus standard iron chelation therapy
Number of subjects: 253
Study 37975839 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education based on individual needs and circumstances
Number of subjects: 0
Study 37975839 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' improved skills in COPD management
Number of subjects: 0
Study 37975923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright blue-green light (12,000 lx)
Number of subjects: 30
Study 37975923 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (5 lx)
Number of subjects: 30
Study 37976067 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 394
Study 37976067 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 394
Study 37976067 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT (Aspirin 100 mg/d + Clopidogrel 75 mg/d)
Number of subjects: 394
Study 37976073 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h-double dose of TDF/FTC (two pills)
Number of subjects: 23
Study 37976073 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days-single dose of TDF/FTC (daily pill)
Number of subjects: 23
Study 37976073 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 2 h-double dose and 7 days-single dose
Number of subjects: 23
Study 37976073 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h-double dose of TDF/FTC
Number of subjects: 23
Study 37976072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg twice daily (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days)
Number of subjects: 1175
Study 37976072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study 37976072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 1175
Study 37976097 — intervention group
Group type: EXPERIMENTAL
Intervention: Wysa for Chronic Pain digital intervention
Number of subjects: 30
Study 37976257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 37976257 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training (CCT)
Number of subjects: 0
Study 37976257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MBSR and CCT
Number of subjects: 0
Study 37976375 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction resistance exercise (BFR-RE)
Number of subjects: 45
Study 37976375 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise without BFR (Control)
Number of subjects: 45
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (median daily dose 4.3 mg/day, mean duration 6.4 days)
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin nonresponse
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic cardiomyopathy (CCM)
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac variables (ratio of early mitral inflow velocity and mitral annular early diastolic tissue doppler velocity > 12.5)
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue doppler mitral velocity < 7 cm/s
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in cardiac index > 20.5% at 72 hours
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment biomarkers (CysC > 2.2 mg/l)
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment biomarkers (N-terminal proBNP > 350 pg/mL)
Number of subjects: 140
Study 37976391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary edema
Number of subjects: 140
Study 37976444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab 600 mg plus atezolizumab 1,200 mg and carboplatin/etoposide (CE)
Number of subjects: 490
Study 37976444 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo plus atezolizumab 1,200 mg and CE)
Number of subjects: 490
Study 37976516 — intervention group
Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 1.0
Number of subjects: 36
Study 37976516 — intervention group
Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 1.5
Number of subjects: 36
Study 37976516 — intervention group
Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 2.5
Number of subjects: 36